NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report sent to investors on Thursday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Price Performance

NASDAQ:NURO opened at $4.27 on Thursday. The firm has a market capitalization of $8.71 million, a P/E ratio of -0.93 and a beta of 2.29. The business has a 50 day simple moving average of $4.08 and a 200 day simple moving average of $3.83. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73.

NeuroMetrix (NASDAQ:NURO) last announced its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. The firm had revenue of $0.59 million for the quarter. During the same period last year, the business posted ($1.66) earnings per share.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.